Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria
Nigerian Medical Journal · 2016-07 · 57 (4) · 246-250
DOI: 10.4103/0300-1652.188362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nigerian Medical Journal, 2016-07. Verfasst von Samson E Isa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Infectious Diseases Unit, University of Jos/Jos University Teaching Hospital, Jos, Plateau State, Nigeria. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Secondary transmission of Lassa fever (LF) occurs in the community and in health-care facilities, and is associated with high fatality in Nigeria. We investigated the role of oral ribavirin postexposure prophylaxis (orPEP) in preventing LF among the primary contacts of confirmed cases from December 2015 to March 2016. Materials and Methods: Epidemiological and clinical data of LF contacts were prospectively collected. However, information regarding ribavirin adverse effects (AEs) were collected retrospectively through a telephone interview. High-risk contacts were clinically monitored orPEP.
Results
Thirty-five (94.6%) out of the 37 individuals enrolled in the study were contacts of confirmed LF cases, and friends and family members (54%) constituted the largest group. However, only 29 (83%) individuals were classified as high-risk contacts. Twenty-one (60%) of contacts were prescribed ribavirin with 6 (28.6%) of them reporting AEs. Body weakness (33%) was the most frequent AE, but there was no incidence of treatment discontinuation due to AE. Furthermore, there were no reported cases of LF among all respondents (0%), whether they had orPEP or not.
Conclusion
Secondary transmission of LF seems uncommon and the benefit of orPEP is uncertain. Although AEs of ribavirin may not be uncommon, they are rarely serious enough to cause treatment interruption. More emphasis should be on supporting persons looking after LF cases adopt measures that minimize the risks of exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Infectious Diseases Unit, University of Jos/Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
- Department of Medical Microbiology, University of Jos/Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
- Department of Microbiology, University of Jos, Jos, Plateau State, Nigeria.
- Department of Internal Medicine, Infectious Diseases Unit, Arnas Civico Di Cristina Benfratelli, Palermo, Italy.
- Department of Pharmaceutical Sciences, Aston University, Birmingham, United Kingdom.
Zitieren
APA
Isa, S. E., Okwute, A., Iraoyah, K. O., Nathan, S. Y., Simji, G. S., Okolo, M. O., Anejo-Okopi, J., Spicola, D., & Isa, D. E. (2016). Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria. Nigerian Medical Journal, 57(4), 246-250. https://doi.org/10.4103/0300-1652.188362
Vancouver
Isa SE, Okwute A, Iraoyah KO, Nathan SY, Simji GS, Okolo MO, et al. Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria. Nigerian Medical Journal. 2016;57(4):246-250. doi:10.4103/0300-1652.188362
BibTeX
@article{Isa2016,
author = {Isa, Samson E and Okwute, Attah and Iraoyah, Kelly O and Nathan, Shehu Y and Simji, Gomerep S and Okolo, Mark O and Anejo-Okopi, Joseph and Spicola, Daria and Isa, Daisy E},
title = {Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria},
journal = {Nigerian Medical Journal},
year = {2016},
volume = {57},
number = {4},
pages = {246--250},
doi = {10.4103/0300-1652.188362}
}
EUVIMED